Key result
Primary microvascular angina is characterized by heterogeneous pathogenetic mechanisms and a generally good prognosis, with various treatments available for symptom control.
Primary microvascular angina is increasingly recognized, has a generally good prognosis, and can be managed with various pharmacological and non-pharmacological strategies.
May guide symptom management in primary microvascular angina; leaves open mechanism-targeted trials.
Microvascular angina (MVA), i.e. angina caused by abnormalities of the coronary microcirculation, is increasingly recognised in clinical practice. The pathogenetic mechanisms of MVA are heterogeneous and may involve both structural and functional alterations of coronary microcirculation, and functional abnormalities may variably involve an impairment of coronary microvascular dilatation and an increased microvascular constrictor activity. Both invasive and non-invasive diagnostic tools exist to identify patients with MVA in clinical practice. Prognosis has been reported to be good in primary MVA patients, although the prognostic implications of coronary microvascular dysfunction (CMVD) in more heterogeneous populations of angina patients need further assessment. Management of primary MVA can be challenging, but pharmacological and non-pharmacological treatments exist that allow satisfactory control of symptoms in most patients.
No takes yet. Share an insight, caveat, or question.
Lanza et al. (2018) conducted a review in Microvascular angina. Primary microvascular angina is characterized by heterogeneous pathogenetic mechanisms and a generally good prognosis, with various treatments available for symptom control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: